Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics,...
-
date post
18-Dec-2015 -
Category
Documents
-
view
216 -
download
0
Transcript of Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics,...
![Page 1: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/1.jpg)
Yeast in drug development
Properties: unicellular eukaryoteMethodology: forward and reverse genetics, two-hybrid
system, surrogate hostApplications: Model system for cellular eukaryotic functions
(animal or plant):Intracellular signal transductionDNA repair, replication, cell cycletranscriptionchromosome biologyprotein transportwater transportetc.
Protein-protein interactionsGlobal transcriptional regulationDrug target identificationDrug screening/selectionDisease diagnosticsModel for fungal pathogens (plant/animal)
![Page 2: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/2.jpg)
Advantages of yeast in molecular biology
• Short life cycle, easy to cultivate• Compact genome, fully sequenced• Many fundamental processes on cellular level conserved• Lots of information available per gene product• Genetically tractable:
• haploid• DNA transformation• multiple genetic markers available, both selection and counterselectionpossible• genetic crosses possible• gene knockout by homologous recombination very efficient –complete set of 4 x 6000 knockout mutants available
![Page 3: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/3.jpg)
Yeast for production of proteins – hepatitis B vaccine
+ =
Advantages:
• higher yield, faster growth than animal cells• eukaryotic post-translational modifications
Hepatitis B surface antigen (HbSAg)
![Page 4: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/4.jpg)
Yeast as a genetically tractable organism to identify drug targets,establish cellular disease models, diagnosis, and for screening ofreceptor ligands and lead compounds
![Page 5: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/5.jpg)
The yeast genomeis densely packedwith genes
Saccharomycescerevisiae is themost information-dense of allexperimentalorganisms
![Page 6: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/6.jpg)
![Page 7: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/7.jpg)
![Page 8: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/8.jpg)
![Page 9: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/9.jpg)
![Page 10: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/10.jpg)
![Page 11: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/11.jpg)
Functional Catalogue version from 06.12.2001 •METABOLISM (1066 ORFs)
•amino acid metabolism (204 ORFs) •amino acid biosynthesis (118 ORFs)
•biosynthesis of the aspartate family (1 ORF) •biosynthesis of lysine (1 ORF)
•biosynthesis of the cysteine-aromatic group (2 ORFs) •biosynthesis of serine (1 ORF)
•biosynthesis of the pyruvate family (alanine, isoleucine, leucine, valine) and D-alanine (1 ORF) •regulation of amino acid metabolism (33 ORFs) •amino acid transport (23 ORFs) •amino acid degradation (catabolism) (35 ORFs)
•degradation of amino acids of the glutamate group (1 ORF) •degradation of glutamate (1 ORF)
•degradation of amino acids of the cysteine-aromatic group (1 ORF) •degradation of glycine (1 ORF)
•other amino acid metabolism activities (5 ORFs) •nitrogen and sulfur metabolism (67 ORFs)
•nitrogen and sulfur utilization (38 ORFs) •regulation of nitrogen and sulphur utilization (29 ORFs)
•nucleotide metabolism (148 ORFs) •purine ribonucleotide metabolism (45 ORFs) •pyrimidine ribonucleotide metabolism (29 ORFs) •deoxyribonucleotide metabolism (11 ORFs) •metabolism of cyclic and unusual nucleotides (8 ORFs) •regulation of nucleotide metabolism (13 ORFs) •polynucleotide degradation (27 ORFs)
•RNA degradation (4 ORFs) •nucleotide transport (14 ORFs) •other nucleotide-metabolism activities (7 ORFs)
•phosphate metabolism (33 ORFs) •phosphate utilization (14 ORFs) •regulation of phosphate utilization (8 ORFs) •phosphate transport (10 ORFs) •other phosphate metabolism activities (1 ORF)
•C-compound and carbohydrate metabolism (415 ORFs) •C-compound and carbohydrate utilization (261 ORFs)
•C-compound, carbohydrate anabolism (1 ORF) •polysaccharide biosynthesis (1 ORF)
•regulation of C-compound and carbohydrate utilization (120 ORFs) •C-compound, carbohydrate transport (42 ORFs) •other C-compound, carbohydrate metabolism activities (2 ORFs)
•lipid, fatty-acid and isoprenoid metabolism (213 ORFs) •lipid, fatty-acid and isoprenoid biosynthesis (119 ORFs)
•phospholipid biosynthesis (2 ORFs) •glycolipid biosynthesis (1 ORF) •isoprenoid biosynthesis (1 ORF)
•tetracyclic and pentacyclic triterpenes (cholesterin, steroids and hopanoids) biosynthesis (1 ORF) •breakdown of lipids, fatty acids and isoprenoids (25 ORFs) •lipid, fatty-acid and isoprenoid utilization (26 ORFs) •regulation of lipid, fatty-acid and isoprenoid metabolism (20 ORFs) •lipid and fatty-acid transport (21 ORFs) •other lipid, fatty-acid and isoprenoid metabolism activities (13 ORFs)
•metabolism of vitamins, cofactors, and prosthetic groups (86 ORFs) •biosynthesis of vitamins, cofactors, and prosthetic groups (63 ORFs) •utilization of vitamins, cofactors, and prosthetic groups (7 ORFs) •regulation of vitamins, cofactors, and prosthetic groups metabolism (3 ORFs) •transport of vitamins, cofactors, and prosthetic groups (3 ORFs) •other vitamin, cofactor, and prosthetic group metabolism activities (8 ORFs)
•secondary metabolism (5 ORFs) •metabolism of primary metabolic sugars derivatives (1 ORF)
•biosynthesis of glycosides (1 ORF) •biosynthesis of secondary products derived from primary amino acids (4 ORFs)
•biosynthesis of amines (4 ORFs)
![Page 12: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/12.jpg)
![Page 13: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/13.jpg)
Pathway and graphical function informationin databases
![Page 14: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/14.jpg)
Genetic engineering of yeast for drug sensitivity assays
Problem:
• Many hydrophobic low Mw compoundsdo not enter the yeast cell
• Yeast has multiple transport proteins involvedIn drug transport: 35 in major facilitator super-family, plus 14 ABC transporters
• Each transporter is highly promiscuous
Solutions:
• make mutants defective in membrane lipidbiosynthesis, e.g. erg6
• make multiple deletions of genes fortransporter proteins.
• Nine-tuple deletant strain 100x moresensitive to wide range of compounds
![Page 15: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/15.jpg)
The ”compendium” approach:
Goal: to identify proteintargets of drugs with unknownmechanism
Principle: disturbance of a pathway bya drug or a mutation should yield similar phenotypes, including on transcript profiles
Method: clustering of transcript profilesof yeast deletion mutants withexperimental conditions
Hughes et al., Cell 102:109 (2000)
![Page 16: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/16.jpg)
Transcript profile clusteringidentifies similarity betweendyclonine treatment anddisruption of ergosterol metabolism
![Page 17: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/17.jpg)
Y’
Gal4AD
X
Gal4DB
HIS3Gal4 bindingsite
The two-hybrid systemGal4AD
X
Gal4DB
HIS3Gal4 bindingsite
Y
No growth on -His medium
Growth on -His medium
Physical interactionbetween hybridproteins activatesreporter gene undercontrol of Gal4 transcription factor
Bait
Prey
![Page 18: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/18.jpg)
Gavin et al. Nature 415:141 (2002)
Network of physical protein complexes in yeast
![Page 19: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/19.jpg)
Internet databases combine physical andgenetic interaction information
![Page 20: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/20.jpg)
Genetic and physical interactions visualised by dedicated software
![Page 21: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/21.jpg)
Y
AD
X
GBDHIS3
Gal4 bindingsite
Y
AD
X
GBDHIS3
Gal4 bindingsite
YAD
Z
LBDURA3
LexA bindingsite
YAD
Z
LBDURA3
LexA bindingsite
Reverse two-hybrid: selection ofinteraction-disrupting agents andmapping of interaction domains
1. a) Mutagenize Y
or
b) Transform withlibrary encoding randompeptides, or add library oforganic compounds
2. Select for 5-FOAR and His+
![Page 22: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/22.jpg)
Extensions of two-hybrid for drug target identification:aptamers and DB-anchored drugs
Selection for aptamers thatbind to the bait
Selection for aptamers thatdisrupt an interaction
Selection for proteins that bindto a drug which is anchored to aDB through a covalent link to anotherdrug
![Page 23: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/23.jpg)
Systematic analysis of synthetic lethalityby SGA – ”synthetic gene arrays”
![Page 24: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/24.jpg)
Network of genetically connectedgene functions
Tong et al., Science 303:808 – 813 (2004)
Two-dimensional hierarchical clustering of the synthetic genetic interactions determined by SGA analysis
SGA analysis clustersrelated genes andfunctional groups
![Page 25: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/25.jpg)
Fig. 3. Toxicity profiles of cytotoxic anticancer agents: topoisomerase poisons, X-rays, bleomycin, and actinomycin D. The graphs show the IC50 (log M for compounds, log k rad for X-rays) for each agent against the strain panel. The vertical line is set at the IC50
of the wild-type strain. The strains are grouped and color-coded according to the DNA damage response pathway they represent.
The ”Seattle Project”
Antitumor treatments (drugs, irradiation) are tested on sets of yeast mutantswhere different DNA repair and DNA damage response pwahtways are inactivated.Hypothesis: synthetic effects if the drug an the mutation in the tumour affect parallell pathways. Goal: individualised tumour therapy
![Page 26: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/26.jpg)
Genetics
Scope
• The causal relationship between the genome (genotype) and properties of
the organism (phenotype)
Scope
• The causal relationship between the genome (genotype) and properties of
the organism (phenotype)
Scope
• The causal relationship between the genome (genotype) and properties of
the organism (phenotype)
Method
•Observe properties of whole system (cell, organism) altered in one (several) genes (Cf. physiology: observe whole system, infer relationship between parts; biochemistry: study gene products in isolation)
![Page 27: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/27.jpg)
Forward genetics
Aim
- To go from function to gene
Means
-Screen populations of mutants for
gain or loss of a particular function
Reverse genetics
Aim
- To define the function(s) of a gene
Means
- Analyze a particular mutant for gain or loss of
a variety of functions
![Page 28: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/28.jpg)
The geneticist's dilemma
• Most mutations are recessive, loss-of-function
• Most mutations confer sensitivity, not resistance to a specific condition
• Screening for resistance is easy, simply selecting will do
• Screening for sensitivity is extremely labor-intensive, involves replica-plating and visual inspection
![Page 29: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/29.jpg)
Control screen: tunicamycin
Step1: Heterozygous mutations in three loci conferred sensitivity:
• ALG7 (Asn-linked glycosyl transferase;
previously known target)
• YMR007w (unknown function)
• YMR266w (membrane transport)
Step 2: test cognate homozygous mutations:
• alg7/alg7 wild-type sensitivity
• ymr007w/ymr007w supersensitive
• ymr266w/ymr266w supersensitive
Ymr007w and Ymr266w ruled out as direct drug
targets because of supersensitivity in the absence of
the gene product
![Page 30: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/30.jpg)
Direct drug effect on target (1)
Output
Normal situation Drug
Smaller output
![Page 31: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/31.jpg)
Direct drug effect on target (2)
Drug
Insufficient output(cell dies)
Haploinsufficiency(less gene product)
Homozygous mutation(no gene product)
Drug
Insufficient output(cell dies)
Insufficient output(cell dies)
![Page 32: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/32.jpg)
Indirect effects (drug binds to gene productrelated to the mutated one)
Output Output
Drug
![Page 33: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/33.jpg)
Indirect effects (2)
Drug
Insufficient output
Haploinsufficiency(heterozygous mutation)
Drug
Insufficient output
Homozygous mutation
![Page 34: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/34.jpg)
Principle of ”molecular bar-codes”:
Synthetic DNA sequence (”tag” or ”bar-code”) is inserted adjacent to site of genomic disruption
Due to flanking common sequences,the bar-code is PCR-amplifiable andcan be hybridized to DNA array
![Page 35: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/35.jpg)
Competition experiments using the ”bar-code” concept
![Page 36: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/36.jpg)
Tunicamycin controlexperiment:
• array hybridization
• quantification
![Page 37: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/37.jpg)
A sensor in yeast for ligand binding
• deletion of the yeast’s own DHFR gene (dhr1) from the genome• insertion in mouse DHFR of heterologous amino acids with binding domains from different proteins• ts variant of DHFR makes the protein extra sensitive to conformationalchanges• binding of ligand gives increased stability of DHFR
Tucker & Fields, Nature Biotechnology 19:1042 (2001)
![Page 38: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/38.jpg)
Growth is selectivefor ligand interaction
Growth correlates withbinding affinity
![Page 39: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/39.jpg)
Yeast-based p53 diagnosis
• p53 is the most commonly mutated gene in human tumors• wide mutation spectrum, many mutated alleles• p53 is transcription factor; functional assay time-saving• variation: ADE2 gene as a reporter. Colony-color based readout(ratio red/white colonies), diagnosis of heterozygous mutations possible
![Page 40: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/40.jpg)
• 7-TM receptor in yeast eliminated• mammalian homolog expressed,interacts with yeast G-protein• large numbers of yeast clones canbe screened efficiently • variety of marker genes makespossible selection both for andagainst interactions
Further improvements:
• express human G-protein insteadof yeast homolog
• delete FAR1 gene to preventcell cycle arrest as a result ofpathway activation
![Page 41: Yeast in drug development Properties:unicellular eukaryote Methodology:forward and reverse genetics, two-hybrid system, surrogate host Applications:Model.](https://reader037.fdocuments.in/reader037/viewer/2022110207/56649d235503460f949f9558/html5/thumbnails/41.jpg)
Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeastChristine Klein et al.
Nature Biotechnology 16, 1334 - 1337 (1998)
• Human formyl peptide receptor like-1 (FPRL-1) receptor expressed in yeast
• Expression of random peptides (13-mers) linked to secretion signal
• Activation of receptor-coupled pathway linked to expression of HIS3 reporter
• Three rounds of selection yielded 5 positive peptides out of 106 initial clones